论文信息 - First‐in‐human study demonstrating the safety and clinical efficacy of novel anti‐IL‐17A monoclonal antibody CJM112 in moderate to severe plaque psoriasis - 字舞流文

First‐in‐human study demonstrating the safety and clinical efficacy of novel anti‐IL‐17A monoclonal antibody CJM112 in moderate to severe plaque psoriasis

I. Rozenberg | C. Calonder | F. D. Di Padova | F. Kolbinger | M. Kaul | J. Rondeau | R. Mussmann | P. Jarvis | P. Espié | M. Aassi | T. Sligh | R. Cebe | T. Huber